Literature DB >> 22527644

[German fibromyalgia consumer reports. Benefits and harms of fibromyalgia syndrome therapies].

W Häuser1, E Jung, B Erbslöh-Möller, M Gesmann, H Kühn-Becker, F Petermann, J Langhorst, T Weiss, R Thoma, A Winkelmann.   

Abstract

BACKGROUND: Consumer reports provide information on benefits and harms in routine clinical care. We report the first fibromyalgia syndrome (FMS) consumer reports in Europe.
MATERIAL AND METHODS: The study was carried out from November 2010 to April 2011. The benefits and harms of pharmacological and non-pharmacological therapies experienced by the patient were assessed in an 11-point Likert scale (0=no, 10=very high benefit or harm) by a questionnaire. The questionnaire was distributed by the German League against Rheumatism and the German Fibromyalgia Association to their members and to all consecutive FMS patients of nine clinical centers of different levels of care.
RESULTS: A total of 1,661 questionnaires (95% women, mean age 54 years) were analyzed. Self-management strategies (distraction, resting, aerobic exercise), physical therapies (warm and pool therapies), psychological therapies (education, psychotherapy), and inpatient multicomponent therapies were judged to be more efficacious and less harmful than all types of pharmacological therapies.
CONCLUSION: The German fibromyalgia consumer reports highlight the importance of non-pharmcological therapies in the long-term management of FMS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22527644     DOI: 10.1007/s00482-012-1161-5

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  21 in total

1.  Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia.

Authors:  Frederick Wolfe; Daniel J Clauw; Mary-Ann Fitzcharles; Don L Goldenberg; Winfried Häuser; Robert S Katz; Philip Mease; Anthony S Russell; I Jon Russell; John B Winfield
Journal:  J Rheumatol       Date:  2011-02-01       Impact factor: 4.666

2.  [Treatment and healthcare costs of fibromyalgia syndrome in Germany: analysis of the data of the Barmer health insurance (BEK) from 2008-2009].

Authors:  U Marschall; B Arnold; W Häuser
Journal:  Schmerz       Date:  2011-08       Impact factor: 1.107

3.  A comparison of the clinical features of fibromyalgia syndrome in different settings.

Authors:  Winfried Häuser; Werner Biewer; Mechthild Gesmann; Hedi Kühn-Becker; Frank Petzke; Hubertus von Wilmoswky; Jost Langhorst; Heide Glaesmer
Journal:  Eur J Pain       Date:  2011-06-08       Impact factor: 3.931

4.  The development of fibromyalgia--I: examination of rates and predictors in patients with rheumatoid arthritis (RA).

Authors:  Frederick Wolfe; Winfried Häuser; Afton L Hassett; Robert S Katz; Brian T Walitt
Journal:  Pain       Date:  2010-10-18       Impact factor: 6.961

5.  [Validation of the German version of the Regional Pain Scale for the diagnosis of fibromyalgia syndrome].

Authors:  W Häuser; S Schild; M Kosseva; S Hayo; H von Wilmowski; R Alten; J Langhorst; W Hofmann; J Maus; H Glaesmer
Journal:  Schmerz       Date:  2010-06       Impact factor: 1.107

Review 6.  Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome.

Authors:  Winfried Häuser; Frank Petzke; Claudia Sommer
Journal:  J Pain       Date:  2010-04-24       Impact factor: 5.820

7.  Diagnosis and differential diagnosis of fibromyalgia.

Authors:  Don L Goldenberg
Journal:  Am J Med       Date:  2009-12       Impact factor: 4.965

8.  A patient survey of the impact of fibromyalgia and the journey to diagnosis.

Authors:  Ernest Choy; Serge Perrot; Teresa Leon; Joan Kaplan; Danielle Petersel; Anna Ginovker; Erich Kramer
Journal:  BMC Health Serv Res       Date:  2010-04-26       Impact factor: 2.655

9.  Fibromyalgia syndrome: classification, diagnosis, and treatment.

Authors:  Winfried Häuser; Wolfgang Eich; Markus Herrmann; Detlev O Nutzinger; Marcus Schiltenwolf; Peter Henningsen
Journal:  Dtsch Arztebl Int       Date:  2009-06-05       Impact factor: 5.594

10.  Patient-reported outcomes as a source of evidence in off-label prescribing: analysis of data from PatientsLikeMe.

Authors:  Jeana Frost; Sally Okun; Timothy Vaughan; James Heywood; Paul Wicks
Journal:  J Med Internet Res       Date:  2011-01-21       Impact factor: 5.428

View more
  15 in total

1.  [Benefits and disadvantages of therapy for fibromyalgia syndrome: new insights and decision aids from consumer reports?].

Authors:  F Petzke
Journal:  Schmerz       Date:  2012-04       Impact factor: 1.107

Review 2.  [Psychotherapeutic procedures for fibromyalgia syndrome].

Authors:  W Häuser; K Bernardy
Journal:  Z Rheumatol       Date:  2015-09       Impact factor: 1.372

Review 3.  Selective serotonin reuptake inhibitors for fibromyalgia syndrome.

Authors:  Brian Walitt; Gerard Urrútia; María Betina Nishishinya; Sarah E Cantrell; Winfried Häuser
Journal:  Cochrane Database Syst Rev       Date:  2015-06-05

Review 4.  [Physiotherapy, occupational therapy and physical therapy in fibromyalgia syndrome : Updated guidelines 2017 and overview of systematic review articles].

Authors:  A Winkelmann; H Bork; W Brückle; C Dexl; P Heldmann; P Henningsen; L Krumbein; V Pullwitt; M Schiltenwolf; W Häuser
Journal:  Schmerz       Date:  2017-06       Impact factor: 1.107

Review 5.  [Drug therapy of fibromyalgia syndrome : Updated guidelines 2017 and overview of systematic review articles].

Authors:  C Sommer; R Alten; K-J Bär; M Bernateck; W Brückle; E Friedel; P Henningsen; F Petzke; T Tölle; N Üçeyler; A Winkelmann; W Häuser
Journal:  Schmerz       Date:  2017-06       Impact factor: 1.107

6.  [Prevalence of chronic pain in Germany. A representative survey of the general population].

Authors:  W Häuser; G Schmutzer; A Hinz; A Hilbert; E Brähler
Journal:  Schmerz       Date:  2013-02       Impact factor: 1.107

Review 7.  Mirtazapine for fibromyalgia in adults.

Authors:  Patrick Welsch; Kathrin Bernardy; Sheena Derry; R Andrew Moore; Winfried Häuser
Journal:  Cochrane Database Syst Rev       Date:  2018-08-06

Review 8.  WITHDRAWN: Anticonvulsants for fibromyalgia.

Authors:  Nurcan Üçeyler; Claudia Sommer; Brian Walitt; Winfried Häuser
Journal:  Cochrane Database Syst Rev       Date:  2017-10-09

9.  [Healthcare services research on pain in Germany. A survey].

Authors:  W Häuser; E Neugebauer; F Petzke
Journal:  Schmerz       Date:  2015-10       Impact factor: 1.107

10.  [Are members of fibromyalgia syndrome self-help groups "different"? Demographic and clinical characteristics of members and non-members of fibromyalgia syndrome self-help groups].

Authors:  E Jung; B Erbslöh-Möller; M Gesmann; H Kühn-Becker; F Petermann; J Langhorst; T Weiss; R Thoma; A Winkelmann; W Häuser
Journal:  Z Rheumatol       Date:  2013-06       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.